Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Engelhardt, Monika  [Clear All Filters]
2024
Zeissig MN, Hewett DR, Mrozik KM, Panagopoulos V, Wallington-Gates CT, Spencer A, Dold SM, Engelhardt M, Vandyke K, Zannettino ACW. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leuk Res. 2024;139:107469.
2023
Tilmont R, Yakoub-Agha I, Eikema D-J, Zinger N, Haenel M, Schaap N, Arroyo CHerrera, Schuermans C, Besemer B, Engelhardt M, et al. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023.
Götz V, Mathé P, Agarwal P, Hornuss D, Pfau S, Panning M, Prager E, Voll RE, Engelhardt M, Frye BC, et al. Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era. Infection. 2023.
Terpos E, Musto P, Engelhardt M, Ntanasis-Stathopoulos I, Sonneveld P, Ludwig H. Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus. Leukemia. 2023.
Gherman R-F, Ewald S, Ihorst G, Strüßmann T, Zeiser R, Wäsch R, Bertz H, Stolz D, Duyster J, Finke J, et al. Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning. Eur J Haematol. 2023.
Wäsch R, Engelhardt M. In search for cure of multiple myeloma. Haematologica. 2023.
Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
Wäsch R, Strüssmann T, Wehr C, Marks R, Meyer PT, Walz G, Engelhardt M. Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis. Ann Hematol. 2023.
Dieterle MPhilipp, Mostufi-Zadeh-Haghighi G, Kus JWilhelm, Wippel C, Brugger Z, Miething C, Wäsch R, Engelhardt M. Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians. Ann Hematol. 2023.
2022
Frank B, Ihorst G, Herget G, Schäfer H, Neubauer J, Calba M-A, Textor D, Möller M-D, Wenger S, Jung J, et al. Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers. Ann Hematol. 2022.
2021
Straka C, Salwender H, Knop S, Vogel M, Müller J, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, et al. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2021.
Duque-Afonso J, Ewald S, Ihorst G, Waterhouse M, Strüessmann T, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Duyster J, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.
2020
Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020.
Javorniczky NRebeka, Wehrle J, Ihorst G, Hupfer V, Aumann K, Pfeifer D, Niemöller C, Bleul S, Pantic M, Werner M, et al. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leuk Res. 2020;98:106454.
2019
Reinhardt H, Otte P, Eggleton AG, Ruch M, Wöhrl S, Ajayi S, Duyster J, Jung M, Hug MJ, Engelhardt M. Avoiding chemotherapy prescribing errors: Analysis and innovative strategies. Cancer. 2019.
Schumacher M, Hieke S, Ihorst G, Engelhardt M. Dynamic prediction: A challenge for biostatisticians, but greatly needed by patients, physicians and the public. Biom J. 2019.
Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019.
2016
Greil C, Follo M, Engelhardt M, Wäsch R. The Use of SNAP Labeling to Study Cell Cycle Oscillatory Proteins. Methods Mol Biol. 2016;1342:201-208.
2015
Kiehl MG, Egerer G, Engelhardt M, Gross B. Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia. Mycoses. 2015.
Lorenz J, Waldschmidt J, Wider D, Follo M, Ihorst G, Chatterjee M, May AM, Duyster J, Rosenwald A, Wäsch R, et al. From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration. Br J Haematol. 2015.
2013
Schnerch D, Follo M, Felthaus J, Engelhardt M, Wäsch R. The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells. PLoS One. 2013;8(9):e74379.